Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Centers Will Change To Meet Requirements Of Personalized Medicine - Von Eschenbach

This article was originally published in The Pink Sheet Daily

Executive Summary

Acting commissioner says agency must streamline regulatory decision making for combination diagnostic and therapeutic products.

You may also be interested in...



Part D Data Sharing Could Help Enable Assessment Of Drug Coverage’s Impact On Overall Heath Care Costs – CMS

Proposed regulation would permit use of payment data for research and “public health functions.”

Biomarkers Consortium To Investigate Lung Cancer, Non-Hodgkins Lymphoma

Public-private biomedical research partnership will also investigate biomarkers in major depressive disorder, diabetes and pre-diabetes.

Patents, Payment, Science: Triple Challenge To Pharmacogenetic Innovation

Current and former Roche scientists discuss personalized medicine.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel